ENLT Overview

Current Stock Performance: Enlight Renewable Energy Ltd (ENLT) shares have surpassed the average analyst 12-month target price of $37.00, trading at $37.71/share, prompting potential analyst reactions regarding valuation adjustments.

Analyst Target Range: Within the Zacks coverage universe, analyst targets for ENLT vary significantly, with one analyst setting a target as low as $27.00 and another as high as $45.00, indicating a standard deviation of $6.782.

Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock is on a trajectory towards higher targets or if it has become overvalued, suggesting a potential need to reassess their positions.

Analyst Ratings Overview: The article references a rating scale from 1 (Strong Buy) to 5 (Strong Sell) for ENLT, reflecting the collective insights of analysts covering the stock, as provided by Zacks Investment Research.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

Earnings Reports Overview: Several companies, including Transdigm Group, GlobalFoundries, and Tencent Music, are set to report their earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.

Transdigm Group (TDG): Expected earnings per share (EPS) of $9.61, a 4.57% increase from last year, but missed previous consensus by -0.22%. The 2025 Price to Earnings (P/E) ratio is 37.37.

GlobalFoundries (GFS): Forecasted EPS of $0.31, a 3.13% decrease from last year, but has consistently beaten expectations. The 2025 P/E ratio is 26.23, indicating potential for higher growth than competitors.

CorMedix Inc. (CRMD): Anticipated EPS of $0.48, reflecting a significant 1060.00% increase year-over-year, with a strong track record of beating expectations. The 2025 P/E ratio is 5.99, suggesting better growth prospects compared to the industry.